Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Immunovant, Inc. IMVT NASDAQ

NASDAQ Global Select • Healthcare • Biotechnology • US • USD

SharesGrow Score
47/100
2/6 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$35.67
+34.4%

Immunovant, Inc. (IMVT) is a Biotechnology company in the Healthcare sector, currently trading at $26.55. It has a SharesGrow Score of 46/100, indicating a mixed investment profile with 2 out of 7 criteria passed.

Analyst consensus target is IMVT = $36 (+34.4% upside).

Valuation: IMVT trades at a trailing Price-to-Earnings (P/E) of -9.8 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 6.9.

Net income is $414M (loss), growing at -39%/yr. Net profit margin is 0% (thin). Gross margin is 0% (+0 pp trend).

Balance sheet: total debt is $98,000 against $707M equity (Debt-to-Equity (D/E) ratio 0, conservative). Current ratio is 11.16 (strong liquidity). Debt-to-assets is 0%. Total assets: $776M.

Analyst outlook: 18 / 23 analysts rate IMVT as buy (78%) — strong consensus.

SharesGrow 7-Criteria breakdown: Value 43/100 (Partial), Growth 15/100 (Fail), Past 0/100 (Fail), Health 100/100 (Pass), Moat 40/100 (Fail), Future 85/100 (Pass), Income ?/100 (Fail).

$35.67
▲ 34.35% Upside
Average Price Target
Based on 23 Wall Street analysts offering 12-month price targets for Immunovant, Inc., the average price target is $35.67, with a high forecast of $50.00, and a low forecast of $16.00.
Highest Price Target
$50.00
Average Price Target
$35.67
Lowest Price Target
$16.00

IMVT SharesGrow Score Overview

57/100
SharesGrow Score
Above average fundamentals
View full scorecard →
VALUE 43/100
Valuation — P/E, PEG, Forward PEG
GROWTH 15/100
Financials — average growth
PAST 0/100
strong — trend
HEALTH 100/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 40/100
Gross margin is + market cap
FUTURE 85/100
Analyst outlook — as buy
INCOME 0/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — IMVT

~
VALUE Partial
43/100
IMVT trades at a trailing Price-to-Earnings (P/E) of -9.8 (S&P 500 average ~25). Forward PEG 6.9 — overvalued. Analyst consensus target is $36, implying +35.6% from the current price $27. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
✗
GROWTH Fail
15/100
IMVT: +0%/yr revenue is, -39%/yr Net income is average growth. weak. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
—
PAST N/A
N/A
No analyst coverage available for this stock.
✓
HEALTH Pass
100/100
Balance sheet IMVT: Debt-to-Equity (D/E) ratio 0 (conservative), Current ratio is 11.16 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✗
MOAT Fail
40/100
IMVT: Gross margin is 0% (+0 pp trend), $5B market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 40/100. ≥ 70 = Pass.
View details →
✓
FUTURE Pass
85/100
Analyst outlook: 18 / 23 analysts rate IMVT as buy (78%). Analyst consensus target is $36 (+35.6% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
—
INCOME N/A
N/A
No analyst coverage available for this stock.

Stock Chart & Stats

Market Data
52-Week Range12.72-29.25
Volume2.28M
Avg Volume (30D)1.34M
Market Cap$5.4B
Beta (1Y)0.67
Share Statistics
EPS (TTM)-2.73
Shares Outstanding$151.57M
IPO Date2019-06-21
Employees362
CEOEric Venker
Financial Highlights & Ratios
Net Income$-413.84M
Operating Income$-438.15M
Total Cash$713.97M
Total Debt$98K
Net Debt$-713.87M
Total Assets$776.22M
Price / Earnings (P/E)-9.7
Analyst Forecast
1Y Price Target$41.00
Target High$50.00
Target Low$16.00
Upside+54.4%
Rating ConsensusBuy
Analysts Covering23
Buy 78% Hold 17% Sell 4%
Price Target Summary
Company Info
CountryUS
ExchangeNASDAQ Global Select
CurrencyUSD
ISINUS45258J1025

Price Chart

Track all markets on TradingView
IMVT
Immunovant, Inc. ↗  ·  NASDAQ Global Select
Healthcare • Biotechnology
12.72 52WK RANGE 29.25

People Also View

KRTX
KRTX
Karuna Therapeutics, Inc.
$329.83
+0.03%
 MDGL
MDGL
Madrigal Pharmaceuticals, Inc.
$524.99
-0.13%
 BPMC
BPMC
Blueprint Medicines Corporation
$129.46
+0.14%
 ACLX
ACLX
Arcellx, Inc.
$114.89
+0.02%
 PTGX
PTGX
Protagonist Therapeutics, Inc.
$104.72
+7.33%
 ISEE
ISEE
IVERIC bio, Inc.
$39.95
+0.38%
 APLS
APLS
Apellis Pharmaceuticals, Inc.
$40.85
+0.02%
 AKRO
AKRO
Akero Therapeutics, Inc.
$54.65
+0.00%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message